New Therapy Flushes Toxic Plaque Buildup From Arteries for the First Time

Cardiovascular disease is the world's leading cause of death, and for decades medicine has managed it primarily by slowing progression — through statins, anti-inflammatories, and RNA-based therapies that fine-tune lipid metabolism. A new clinical finding suggests a more ambitious approach may now be within reach: actually removing the biological damage already embedded in artery walls.

At the American Heart Association Vascular Discovery Scientific Sessions, Cyclarity Therapeutics presented early human trial data for its drug UDP-003. The therapy targets 7-ketocholesterol (7KC), a toxic oxidized form of cholesterol that accumulates inside atherosclerotic plaques, fueling inflammation, cell death, and vascular instability. Unlike standard cholesterol-lowering drugs, UDP-003 is engineered to physically capture 7KC using a ring-shaped molecule called a cyclodextrin, rendering it water-soluble so the kidneys can excrete it through urine.

Lead investigator Dr. Stephen Nicholls of the Monash Victorian Heart Institute described the initial data as the first evidence of safe oxidized cholesterol excretion in humans — a potential step toward reversing atherosclerosis rather than simply managing it. The company's framing is vivid and instructive: this is about removing rust, not just slowing corrosion.

For longevity science, the implications extend beyond the heart. Arterial aging affects the brain, kidneys, muscles, and metabolic function — systems that collectively determine healthspan. The ability to clear accumulated vascular damage aligns directly with a growing movement in aging research toward targeting the root causes of biological decline rather than downstream symptoms.

Important caveats apply. This is early-phase clinical data, presented at a conference rather than peer-reviewed publication. Safety of excretion has been demonstrated, but efficacy in reducing plaque burden or improving clinical outcomes remains to be shown in larger trials. Still, the conceptual shift — from disease management to damage clearance — marks a meaningful moment in cardiovascular and longevity medicine.